by Until LabsUS
Reversible organ cryopreservation via vitrification at –130°C and magnetic rewarming. Extends viability from hours to weeks for transplant.
Neural tissue electrical recovery shown Sept 2024; Series A funding (Sept 2025) for whole-organ testing.
Updated Sep 2024Checked 10 Oct0 updates this week
The organ is perfused with a cryoprotectant solution that replaces water in cells and tissues, lowering the freezing point and preventing ice crystal formation.
Cooling to –130°C is slow enough and the cryoprotectant concentration high enough that water solidifies into amorphous glass instead of ice crystals.
Alternating magnetic fields generate heat throughout the organ uniformly, avoiding hot spots and temperature gradients that damage tissue.
| Spec | Reversible organ cryopreservation |
|---|---|
| Cryopreservation temperature | –130°CR (reported) |
| Total funding raised | $100M+R (reported) |
R reported by the company
Until Labs
Organ cryopreservation, vitrification, magnetic rewarming, transplant
Until Labs develops reversible organ cryopreservation technology using vitrification (turning water to glass without ice crystals) to extend the time donor organs remain viable for transplant from hours to weeks. The company is led by Laura Deming and Hunter Davis.
